Alvotech SA (ALVO) reported better-than-expected financial results for the third quarter of fiscal 2025. The company's earnings per share (EPS) of $-0.02 matched Wall Street's consensus estimate, while revenue of $0.1 billion also aligned with expectations.
This update provides insight into Alvotech's operational performance as it develops a pipeline of biosimilar medicines aimed at treating various therapeutic areas, including inflammatory diseases and oncology. The firm is focused on monoclonal antibodies, with eight biosimilar candidates currently under development.
Alvotech will host an earnings conference call to discuss these results further and provide additional commentary on its business performance. Investors may find it beneficial to review the full earnings release and listen to management's insights for a comprehensive understanding of the quarter's performance and future outlook.
As of November 8, 2025, Alvotech has a market capitalization of $1.7 billion and a trailing twelve-month price-to-earnings ratio of 27.20. The company is expected to announce its next earnings on May 5, 2026, followed by another report on August 11, 2026.